Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval Mr. Hauser added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback